Skip to main content
Premium Trial:

Request an Annual Quote

UNM, Senomyx, Cadus, UC, and Caliper Among Recent Recipients of US Patents


The Science and Technology Corporation at the University of New Mexico has been awarded US Patent No. 7,018,846, "Display of receptors and analysis of binding interactions and drug libraries."

Inventors listed on the patent are Larry Sklar, Eric Prossnitz, Janeen Vilven, and Donna Neldon.

According to its abstract, the patent protects a display and method of preparing 7-transmembrane and other receptors for real-time kinetic analysis of binding interactions. The invention includes display on beads and in micelles for multi-well and flow cytometric analysis. The invention is useful for ligand discovery and drug action discovery, and G-protein response in particular, the abstract states.

Senomyx has been awarded US Patent No. 7,022,488, "Functional coupling of T1Rs and T2Rs by Gi proteins, and cell-based assays for the identification of T1R and T2R modulators."

Inventors listed on the patent are Guy Servant, Mark Ozeck, Paul Brust, and Hong Xu.

According to its abstract, the patent protects cell-based assay methods for identifying compounds that modulate the activity of specific T1R or T2R taste receptors or which modulate the effect of other T1R or T2R modulators on T1R or T2R activity. These assay methods preferably detect the effect of a putative T1R or T2R modulator compound on MAPK activation, cAMP accumulation, or adenylyl cyclase activity or another signaling pathway regulated by Gi proteins. The level of MAPK activation, cAMP accumulation, or adenylyl cyclase is preferably determined by immunoassay methods that use ligands (monoclonal or polyclonal antibodies) that specifically bind an activated (phosphorylated) MAPK, cAMP, or adenylyl cyclase, the abstract states.

Cadus Technologies has been awarded US Patent No. 7,022,513, "Cell-based signal generation."

Inventors listed on the patent are Jun Xu and Joshua Trueheart.

According to its abstract, the patent protects a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e.g., when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell. Thus, the cell provides a signal generation means comprising a novel fusion protein, the expression of which is independent of stimulation/activation of the signal transduction pathway, but the activity of which is responsive to the signal transduction pathway, the abstract states.

The University of California has been awarded US Patent No. 7,022,826, "Non-oligomerizing fluorescent proteins."

Inventors listed on the patent are Roger Tsien, David Zacharias, and Geoffrey Baird.

According to its abstract, the patent protects a non-oligomerizing fluorescent protein, which is derived from a fluorescent protein having at least one mutation that reduces or eliminates the ability of the protein to oligomerize. The non-oligomerizing fluorescent protein can be derived from a naturally occurring green fluorescent protein, red fluorescent protein, or other fluorescent protein related thereto. The patent also protects a fusion protein, which includes a non-oligomerizing fluorescent protein linked to at least one polypeptide of interest. In addition, the patent discloses a polynucleotide encoding a non-oligomerizing fluorescent protein, and a recombinant nucleic acid molecule, which includes a polynucleotide encoding a non-oligomerizing fluorescent protein operatively linked to at least a second polynucleotide. Vectors and host cells containing such polynucleotides also are provided, as are kits containing one or more non-oligomerizing fluorescent proteins or encoding polynucleotides or constructs derived therefrom. The patent also provides methods of making and using the proteins and polynucleotides, the abstract states.

Caliper Life Sciences has been awarded US Patent No. 7,024,281, "Software for the controlled sampling of arrayed materials."

Garrett Unno is the lone inventor listed on the patent.

According to its abstract, the patent protects computer-implemented methods for contacting or sampling materials in arrays having x materials sites with microfluidic devices having n capillary elements. Devices, integrated systems, and computer program products for performing these methods are also provided, the abstract states.


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.